Beam Therapeutics BEAM Contingent Consideration Liability (Non-Current)
Contingent Consideration Liability (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's contingent consideration liability (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's contingent consideration liability (non-current)?
- Beam Therapeutics (BEAM) reported contingent consideration liability (non-current) of $5.45M in Q1 2026.
- How has Beam Therapeutics's contingent consideration liability (non-current) changed year-over-year?
- Beam Therapeutics's contingent consideration liability (non-current) increased by 370.6% year-over-year, from $1.16M to $5.45M.
- What does contingent consideration liability (non-current) mean?
- This represents the estimated fair value of future payment obligations arising from business acquisitions, contingent upon the achievement of specific clinical, regulatory, or commercial milestones. It reflects long-term financial commitments that are not expected to be settled within the next twelve months. Investors monitor this to assess potential future cash outflows and the company's historical success in meeting performance-based acquisition targets.